HIV /AIDS:ARV MEDICINES IMPROVES CD4,DECREASE VIRAL LOAD-LEAD TO ALMOST A NORMAL LIFE EXPECTANCY IN HIV PATIENTS

PROF.DRRAM ,HIV/AIDS,SEX DIS.,SEX WEAK.& ABORTION SPECIALIST
profdrram@gmail.com,+917838059592,+919832025033,DELHI –NCR,IND
HIV/ AIDS,CANCER LATEST MEDICINES AVAILABLE AT CHEAP RATE.
FOLLOW ON FACE BOOK:www.facebook.com/ramkumar
FOLLOW ON TWITTER:www.twitter.com/profdrram

HIV is better controlled by GOOD ARV MEDICINES IF TAKEN REGULARLARLY,NOW A DAYS GOOD LESS TOXIC MEDICINES IS AVAILABLE IF TAKEN REGULARLARLY IT INCREASES CD4 COUNT AND DECREASES VIRAL LOAD AND ULTIMATELY PERSON BECOME FREE OF INFECTION DOESNOT GET OPPURTUNISTIC INFECTIONS AND AS A RESULT LIVES A NORMAL LIFE.

In the UK, where ART is free and available in an established National Health Service, people living with HIV infection can expect to live as long as the general population if successfully treated. Our study showed that longevity depends on both restoration of CD4+ cell count to near normal levels and suppression of the virus to undetectable levels in peripheral blood.
Life expectancy of HIV-positive individuals treated with antiretroviral therapy (ART) in the UK improved by nearly 16 years between 1996 and 2008. Although some groups of HIV-positive individuals may expect to live a similar life span to that of the general population, others have reduced life expectancy due to the impact of late diagnosis and late initiation of ART. A previous study estimated life expectancies of HIV patients in the UK stratified by CD4+ cell count at ART start,but not gains in years of life in response to ART. A European study showed that successfully treated patients who attained a CD4+ cell count more than 500 cells/μl have a standardized mortality ratio (SMR) approaching .However, SMRs are more difficult to communicate to patients than life expectancies and not all patients attain a CD4+ cell count more than 500 cells/μl.The lower limit of the normal CD4+ cell count range is below 500 cells/μl, and therefore exceeding this level might be an unrealistic target for patients who had low preinfection counts. Furthermore, viral suppression is an important factor in treatment success and virological replication may have an effect on prognosis that is independent of CD4+ cell count.
We aimed to investigate the improvement in life expectancy due to CD4+ cell count restoration and viral suppression in patients on ART. We used data from the UK Collaborative HIV Cohort (UK CHIC) Study, on HIV-positive individuals in care in the UK between 2000 and 2012, to estimate life expectancy of those treated for HIV-infection at different durations of ART according to latest CD4+ cell count and viral suppression status.